Nektar Therapeutics (NKTR) — Stock Score Summary

Nektar Therapeutics (NKTR) has a MoatMap StockRank of 28/100 based on Quality (32/100), Value (38/100), and Momentum (45/100) factor scores. The current signal is SELL. Biotechnology companies typically involve binary outcomes, high R&D, and significant capital needs, conflicting with the 'quality compounder', 'asset-light', and 'long reinvestment runway' criteria for consistent, predictable growth.

Nektar Therapeutics is a biopharmaceutical company focused on developing innovative new medicines for serious diseases including cancer, autoimmune conditions, and chronic pain. The company differentiates itself through its proprietary polymer conjugation technology platform, which is designed to improve the therapeutic properties of small molecules and biologics, addressing significant unmet medical needs.

Key Financial Metrics

Price$65.01
Market Cap$2.2B
P/E (Forward)-5.22
Price/Book2.81
Return on Equity-53.6%
Return on Invested Capital-57.0%
Debt/Equity24.89
Gross Margin100.0%
Operating Margin-352.3%
Revenue Growth3.8%

Nektar Therapeutics operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Nektar Therapeutics’s (NKTR) StockRank?
MoatMap’s StockRank for Nektar Therapeutics (NKTR) is 28/100, with a Sell signal. It is a composite of Quality (32), Value (38), and Momentum (45) factor ranks across MoatMap’s 19,000+ stock universe.
Does Nektar Therapeutics have an economic moat?
Nektar Therapeutics (NKTR) has a Quality factor score of 32/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Nektar Therapeutics a buy, hold, or sell?
MoatMap’s current signal for Nektar Therapeutics (NKTR) is Sell, based on a StockRank of 28/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Nektar Therapeutics in?
Nektar Therapeutics (NKTR) operates in the Healthcare sector, specifically the Biotechnology industry (United States).
Browse all ranked stocksNKTR deep dive reportAI ChampionsHow we score stocksSense-check another stock